



CooperVision®



# Progress in Focus: The Global Impact of MiSight® 1 day

2012 – 2025 IMPACT REPORT

Recognizing more than a decade of clinical innovation,<sup>1-10</sup> global influence, and life-changing potential for children with myopia<sup>1</sup>

MiSight® 1 day

Product, indications for use, and regulatory approvals vary by country. Please consult your local CooperVision representative or regulatory authority for region-specific information.



## VIOLET'S STORY

### TABLE OF CONTENTS

- 2 Changing the Trajectory of Myopia
- 3 A Clear Vision: The MiSight® 1 day Journey
- 5 Global Reach and Scale
- 6 Scientific and Clinical Leadership
- 7 Professional Education and Advocacy
- 8 Industry Leadership and Partnerships

*“Wearing MiSight® 1 day contact lenses makes me feel confident because I don’t have to worry about my eyes getting worse, and I can still do all the things I want to do.”* — **Violet, Age 8**

*“I mean, we can’t control that Violet has myopia because as we know myopia is caused by genetic and environmental factors.<sup>11</sup> But one thing we can do right now, one thing we can do right at this moment is to take control and be proactive in slowing the progression of her myopia.<sup>12,13,14</sup> So, that’s why we choose MiSight® 1 day contact lenses for Violet.”* — **Violet’s Dad**

**With the development of MiSight® 1 day, the world's first soft contact lens that's proven to slow myopia progression in children,\*<sup>1</sup> CooperVision set out to change the trajectory of childhood myopia. The clinical trial that led to the approval of MiSight® 1 day began in 2012,<sup>1</sup> and since then, the lens has become more than just a breakthrough product.\*<sup>1</sup> It has helped sparked a global movement, uniting researchers, eye care professionals, public health advocates, and families in a shared mission to safeguard children's vision.**

This report captures CooperVision's milestones, data, and stories that have defined that journey. It reflects CooperVision's unwavering commitment to clinical innovation,<sup>1-10</sup> global collaboration, and equitable access to care. Above all, it shows how MiSight® 1 day continues to lead the way in myopia management.\*<sup>11</sup> and helping to create a healthier future for children around the world.

But this is more than a summary of what we've accomplished. It's a testament to what's possible when science leads, vision guides, and progress stay in focus. It's our promise to the ophthalmic and pediatric health communities: **we're not slowing down.**

With childhood myopia rates rising around the world,<sup>15</sup> CooperVision remains focused on the future, investing in innovation, advocating for global standards of care, and expanding access to proven solutions. We're proud to support eye care professionals in reshaping how the world views myopia: not simply as a condition to correct, but a disease to manage.<sup>16</sup>

Comprehensive myopia management<sup>17</sup> begins with early identification and education, and includes appropriate vision correction and proven myopia control options like MiSight® 1 day.\*<sup>1</sup> This approach helps reduce the risk of serious eye health complications,<sup>18-21</sup> minimizes future dependence vision correction for higher levels of myopia, and supports children's physical, academic, and emotional wellbeing.<sup>22-24</sup> It's an investment in their long-term ocular health<sup>25</sup> and quality of life.<sup>23, 24</sup>

We envision a world where every child with myopia has the opportunity for their eyes to remain healthy for as long as possible through innovation, driven by partnership, and sustained by our collective commitment to change.<sup>18-21, 25</sup>

Thank you for being part of this journey and for all that you're doing to help create a clearer, brighter future for children everywhere.

Live Brightly,



**Jennifer Lambert,**  
VP, Myopia Management & Cornea Care, CooperVision



\* Compared to a single vision 1 day lens over a 3-year period.

† Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ? 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

## A CLEAR VISION: THE MISIGHT® 1 DAY JOURNEY

From breakthrough idea to global impact, CooperVision has been at the forefront of myopia management

### IMPACT YOU CAN SEE (2024-2025)

- ✓ The 7-year efficacy study concludes, and results are published,<sup>3</sup> confirming long-term safety and success
- ✓ In clinical studies, children wore MiSight® 1 day for nearly 7 million wearing hours<sup>26</sup>
- ✓ New partnerships and support tools launch globally, including The Myopia Collective in the U.S. and the WCO CooperVision Myopia Management Navigator
- ✓ MiSight® 1 day becomes the #1 most-fitted soft contact lens approved for myopia control in children<sup>†27</sup>
- ✓ MiSight® 1 day becomes the first soft contact lens for myopia control approved in Japan, further expanding access to myopia management
- ✓ More than 200,000 children worldwide now wear MiSight® 1 day contact lenses<sup>28</sup>
- ✓ Children wearing MiSight® 1 day have collectively reached 550 million hours annually<sup>§26</sup>

### 2000 – 2011: THE VISION BEGINS

- 2005** Anstice & Philips published their early studies<sup>29</sup> on dual-focus technology and present dual-focus results at the EVER Conference
- 2009** MiSight® 1 day received CE Mark approval for the correction of myopia and slowing its progression, marking the first regulatory clearance of its kind. It then launched in Hong Kong
- 2011** MiSight® 1 day availability expanded to Australia, New Zealand, Singapore, and Malaysia

### 2012–2014: CLINICAL TRIAL INITIATED

- The pivotal clinical trial began, laying the foundation for the world's first approved myopia control soft contact lens
- MiSight® 1 day was introduced to a limited number of practices in Iberia

### 2017: A MAJOR MILESTONE

- The 3-year pivotal trial concluded; results show MiSight® 1 day to be effective in slowing the progression of myopia in children<sup>1</sup>

### 2017–2018: GROWING AROUND THE GLOBE

- 3-year trial results presented at the British Contact Lens Association (BCLA) Clinical Conference & Exhibition
- MiSight® 1 day availability expanded across Europe
- CooperVision launched the Asia Pacific Myopia Management Symposium (APMMS), strengthening regional collaboration and thought leadership



† Based on available fit data in the UK and US for patients under 20.

§ Based on actual wearing hours as reported by study participants, plus estimated wearing hours for current total real-world wearers, assuming compliance with wearing times as per the indication.



## 2019: EXPANDING GLOBAL APPROVALS

MiSight® 1 day became the first and only FDA-approved intervention to slow myopia progression in children 8-12 at the initiation of treatment<sup>\*\*\*††</sup>

- The 3-year randomized clinical trial results published in *Optometry and Vision Science*<sup>1</sup>
- MiSight® 1 day received regulatory approval in China for the correction of myopia and slowing its progression in children Management Symposium (APMMS), strengthening regional collaboration and thought leadership<sup>\*\*</sup>

## 2020–2025: FULL SPEED AHEAD

- 6-year data presented, proving long-term effectiveness<sup>2</sup> in slowing myopia progression and supporting the sustained safety of MiSight® 1 day over time
- MiSight® 1 day launched in the U.S. following FDA approval<sup>§§</sup>
- MiSight® 1 day received regulatory approval in Taiwan for slowing myopia progression in children
- Global education, eye care professional (ECP) training, and awareness campaigns gained global momentum
- CooperVision worked with the World Council of Optometry (WCO) to pass a resolution supporting myopia management as the standard of care<sup>16</sup>
- CooperVision joined the International Agency for Prevention of Blindness (IAPB) to advocate for early detection and treatment of myopia in children
- Parameter range expanded to include higher minus powers, allowing more children to benefit from myopia management with MiSight® 1 day
- MiSight® 1 day became part of the plastic neutrality program with Plastic Bank<sup>\*\*\*\*††††††††††30, 31</sup>
- MiSight® 1 day is approved for myopia control in over 40 countries
- CooperVision funds a four-year PhD program at The University of Manchester to research the health economics of myopia control

## EYES ON WHAT'S NEXT

- Continued global expansion
- Working toward national health system integration in select markets
- Public health-level impact, hundreds of thousands of kids helped and counting!<sup>28</sup>

## RESEARCH

2025	<a href="#">Optical Characterisation and Vision Quality Assessment of Two Myopia Control Contact Lenses</a>
2025	<a href="#">Eye Growth and Myopia Progression Following Cessation of Myopia Control Therapy with a Dual-focus Soft Contact Lens</a>
2025	<a href="#">Accommodative Behaviour and Retinal Defocus in Highly Myopic Eyes Fitted with a Dual Focus Myopia Control Contact Lens</a>
2024	<a href="#">Six-year Cumulative Treatment Effect and Treatment Efficacy of a Dual Focus Myopia Control Contact Lens</a>
2023	<a href="#">Six Years of Wearer Experience in Children Participating in a Myopia Control Study of MiSight® 1 day</a>
2023	<a href="#">Myopia Control Dose Delivered to Treated Eyes by a Dual Focus Myopia Control Contact Lens</a>
2022	<a href="#">Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial</a>
2021	<a href="#">Ocular Health of Children Wearing Daily Disposable Contact Lenses Over a 6-year Period</a>
2021	<a href="#">Axial Length Targets for Myopia Control</a>
2021	<a href="#">Adverse Event Rates in the Retrospective Cohort Study of Safety of Paediatric Soft Contact Lens Wear: the ReCSS Study</a>
2019	<a href="#">A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control</a>



MiSight® 1 day is approved for myopia control in over 40 countries



7-year Efficacy Study Published confirmed long-term safety<sup>3</sup>

\*\* U.S. Indications for Use: MiSight® 1 day (omafilcon A) Soft (Hydrophilic) Contact Lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

†† Compared to a single vision 1-day lens over a 3-year period.

‡‡ China Indication for Use: MiSight® 1 day (omafilcon A) soft contact lenses are indicated for the correction of myopia and for slowing the progression of myopia in children who, at the initiation of treatment, are 8-12 years old and have myopia of -0.75 D to -4.00 D (spherical equivalent) with ≤ 1.00 D of astigmatism. Lenses are to be discarded after each removal.

§§ U.S. Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

\*\*\* Net plastic neutrality is established by purchasing credits from Plastic Bank. A credit represents the collection and conversion of one kilogram of plastic that may reach or be destined for waterways. CooperVision purchases credits equal to the weight of plastic in participating brand orders in a specified time period. Plastic in participating brand plastic is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink). Life-improving benefits refer to support provided to eligible Plastic Bank collectors and their family members through CooperVision's funding of Plastic Bank programs, which may include access to vision care, grocery vouchers, and other essentials.

††† MiSight® 1 day orders includes products sold and distributed by CooperVision in participating countries.

‡‡‡ Net plastic neutrality is established by purchasing credits from Plastic Bank. A credit represents the collection and conversion of one kilogram of plastic that may reach or be destined for waterways. CooperVision purchases credits equal to the weight of plastic in MiSight® 1 day orders in a specified time period. MiSight® 1 day plastic is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink)

## GLOBAL REACH AND SCALE OF IMPACT

### CooperVision Leads the Charge Against the Myopia Epidemic<sup>32</sup>

Myopia is a pressing health challenge.<sup>15</sup> Considered to be of epidemic proportions,<sup>33, 34</sup> today the condition affects nearly one in three children worldwide<sup>§§§33</sup> and is expected to rise dramatically over the next few years. By 2050, it's predicted that nearly five billion people will have myopia, with nearly one billion expected to have high myopia.<sup>15</sup>

Having identified this trend early, CooperVision has focused on delivering evidence-based<sup>2, 4-9, 35, 36</sup> easy to fit interventions that empower eye care professionals to make a meaningful difference in children's lives. CooperVision's MiSight® 1 day contact lenses represent a groundbreaking advance<sup>\*\*\*\*1</sup> in this effort and the impact is far-reaching: more than 200,000 children worldwide wear

MiSight® 1 day contact lenses,<sup>28</sup> contributing to 550 million hours of cumulative annual wear time globally.<sup>+++26</sup> Children are prescribed MiSight® 1 day for myopia control in more than 40 countries, reflecting its recognition for safety and efficacy,<sup>###1, 2, 4, 37</sup> and the growing global awareness of pediatric myopia management.<sup>16, 38, 39</sup>

Together, this scale and commitment are shifting the paradigm, from simply correcting vision to actively managing myopia and slowing its progression. The momentum behind MiSight® 1 day is helping to drive a global shift in pediatric eyecare, helping children worldwide<sup>28</sup> see clearly today and into the future. There is a growing consensus that eye care professionals have a responsibility to correct refractive error, but also to prescribe interventions that can help slow the progression of myopia.<sup>16, 38, 39</sup>

## A WORLD OF CONFIDENCE: PRESCRIBED FOR MYOPIA CONTROL IN 40+ COUNTRIES

- Andorra
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Chile
- China
- Colombia
- Costa Rica
- Czech Republic
- Denmark
- Finland
- France
- Germany
- Hong Kong
- Hungary
- Iceland
- Ireland (Republic)
- Israel
- Italy
- Luxembourg
- Malaysia
- Mexico
- Netherlands
- New Zealand
- Norway
- Panama
- Poland
- Portugal
- Russia
- Slovakia
- Slovenia
- Singapore
- South Africa
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- United Kingdom
- United States



§§§ Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.

\*\*\*\* Compared to a single vision 1 day lens over a 3-year period.

+++ Based on actual wearing hours as reported by study participants, plus estimated wearing hours for current total real-world wearers, assuming compliance with wearing times as per the indication.

### IMPORTANT SAFETY INFORMATION: In clinical studies, CooperVision's Myopia Management products are demonstrated to be safe and effective, when worn as directed. Consult your eye care professional and [Patient Information Booklet] prior to use.



## SCIENCE AND CLINICAL LEADERSHIP

*“The strength of MiSight® 1 day lies not just in its innovation, but in the rigor of the science behind it, and we are committed to making that science accessible and easily translatable for the eye care professional community. Our goal has always been to provide clarity that helps practitioners explain the benefits clearly and set realistic expectations for parents.”*

**Paul Chamberlain**, Senior Director, Research Programs, CooperVision

### A Legacy of Scientific Leadership

CooperVision is leading the field in advancing the science of myopia control.<sup>1-10</sup> Backed by the longest-running clinical trial of its kind, extensive peer-reviewed validation—including the influential 2019 study published in *Optometry and Vision Science*—and CooperVision’s global commitment to evidence-based care, MiSight® 1 day continues to set the standard for safety, efficacy,<sup>††††1, 2, 4, 37</sup> and impact in pediatric myopia management.<sup>‡27</sup>

### Proven Over Time

- **7-Year Clinical Trial:** MiSight® 1 day has been studied extensively and is supported by seven years of robust clinical evidence<sup>40</sup>
- **2,300+ children** across multiple countries have participated in MiSight® 1 day clinical studies<sup>40</sup> to date
- Children have worn MiSight® 1 day for nearly **7 million cumulative hours** in clinical research<sup>26</sup> to date
- Prior treatment effects were retained after treatment ends, reinforcing long-term safety and sustained benefit<sup>§§§§34, 41</sup>

### Research Partners

**CooperVision partners with leading researchers to advance innovation, including but not limited to:**

- Centre for Ocular Research & Education (CORE), University of Waterloo – Canada
- National University Hospital / Ophthalmology Dept. – Singapore
- School of Optometry, Aston University – United Kingdom
- Clinical and Experimental Optometry Research Lab, University of Minho – Portugal
- Visioncare Research (Contract Research Organization) – United Kingdom
- The University of Auckland – New Zealand

### Peer-Reviewed and Globally Recognized

- 20+ peer-reviewed publications validating MiSight® 1 day’s safety and efficacy recognized by major regulatory bodies and supported by long-term, peer-reviewed evidence<sup>1-3, 10, 42</sup>
- Myopia management is now recognized as a standard of care by professional bodies<sup>16, 38, 39</sup> supporting eye care professionals in North America, Europe, Asia-Pacific, and Latin America, and includes the World Council of Optometry (global), American Optometric Association (U.S.), College of Optometrists (U.K), and Asia Optometric Congress (Asia)

### A Clinical Journey: The MiSight® 1 day Trilogy

- **3-Year Results:** MiSight® 1 day significantly slowed myopia progression and axial elongation versus single vision lenses,<sup>1</sup> *A 3-Year Randomized Clinical Trial of MiSight Lenses for Myopia Control* (Chamberlain et al., *Optom Vis Sci*, 2019) remains one of the most widely cited papers in the field of pediatric myopia management
- **6-Year Results:** Continued effectiveness over time;<sup>\*\*\*\*\*2</sup> children who began treatment later also showed benefit,<sup>2, 43</sup> *Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-Year Multicenter Clinical Trial* (Chamberlain et al., *Optom Vis Sci*, 2022)
- **7-Year Results:** No rebound in progression after stopping lens wear<sup>†††††35, 41</sup>—an important milestone in long-term safety and efficacy, *Eye Growth and Myopia Progression Following Cessation of Myopia Control Therapy with a Dual-Focus Soft Contact Lens* (Chamberlain et al., *Optom Vis Sci*, 2025)

### Approval Milestones for MiSight® 1 day, (including but not limited to):

- **2009:** CE mark in Europe<sup>†††</sup>
- **2019:** FDA-approval in the U.S.<sup>§§§</sup>
- **2020:** Taiwan FDA approval<sup>\*\*\*\*</sup>
- **2021:** Chinese NMPA approval<sup>††††</sup>
- **2025:** Japan Ministry of Health, Labor and Welfare approval<sup>††††</sup>
- Supported by **robust clinical evidence** and more than a decade of **real-world experience** in myopia management

§§§§ 12 months post-treatment, evidence indicates that no accumulated myopia control benefits were lost following 3 or 6-years of MiSight® 1 day wear (on average, for children aged 8-15 at start of wear). Instead, eye growth reverted to expected, age-normal rates.

\*\*\*\*\* No clinically meaningful change in refractive error (-0.25D or less from baseline). Lenses fitted between the ages of 8-12.

††††† 12 months post-treatment, evidence indicates that no accumulated myopia control benefits were lost following 3 or 6-years of MiSight® 1 day wear (on average, for children aged 8-15 at start of wear). Instead, eye growth reverted to expected, age-normal rates.

# PROFESSIONAL EDUCATION AND ADVOCACY

## Professional Education and Advocacy

CooperVision is committed to equipping eye care professionals and communities with the tools, knowledge, and clinical evidence to help them embrace myopia management and build confidence in treating children with progressive myopia. Through multi-channel education and global outreach efforts, the company is helping to build a more informed, proactive, and engaged myopia care ecosystem, one that empowers both providers and parents alike.

## Advancing Eye Care Professional Education

CooperVision invests deeply in professional development, offering ongoing education that meets eye care professionals where they are, including at their practice, at conferences, and online.

### • Active presence at 60+ national and international optometry and ophthalmology conferences, including:

- 100% Optical, United Kingdom
- American Academy of Optometry Annual Meeting (AAOptom)
- Asia-Pacific Myopia Management Symposium (APMMS)
- The Association for Research in Vision and Ophthalmology (ARVO)
- British Contact Lens Association Clinical Conference and Exhibition (BCLA)
- European Academy of Optometry and Optics (EAOO)
- Global Specialty Lens Symposium (GSLs)
- Global Myopia Symposium (GMS)
- The International Congress of Ophthalmology and Optometry China (COOC)
- International Myopia Conference (IMC)
- Netherlands Contact Lens Congress (NCC)
- SECO International (SECO)
- World Congress of Paediatric Ophthalmology & Strabismus (WCPOS)

## Driving Public Awareness

Beyond the clinic, CooperVision helps raise awareness of myopia and its impact through consumer campaigns and earned media strategies:

- **Significant parent and eye care professional reach**, with millions of media impressions across video, print, digital, and social channels
- **Strategic media partnerships** with parenting, health, and education-focused outlets to stress the importance of early myopia intervention
- **Influencer and advocate collaborations**, sharing personal stories to drive authentic engagement
- **Localized awareness initiatives**, aligned with back-to-school, World Sight Day, Myopia Awareness Week, Myopia Action Month, and Children's Vision Month to increase awareness at critical times of year
- **Educational content hubs** on platforms like YouTube and regional websites offering resources on myopia prevention and management

## EDUCATIONAL PROGRAMMING DELIVERED THROUGH:



**Ongoing live events and workshops** hosted in major markets



**Multiple on-demand digital platforms** with clinical modules and case studies



**In-practice support tools** for patient conversations and clinical integration



**Regular webinars and peer-to-peer learning sessions** featuring global key opinion leaders and researchers

## What would you tell another eye care professional who's just getting started in myopia management?

*"Embrace the challenge. Be patient. And always embrace the well-being of your patients."*

### **Dr. Li Lian Foo, Singapore**

Clinical Assistant Professor, Duke-NUS Graduate Medical School, Consultant Ophthalmologist, Singapore National Eye Centre

*"We have a responsibility to offer the best possible care, and for children with myopia, this is it. Learn the treatment options, build your communication skills, and most importantly, take that first step. Just begin."*

### **Dr. Elena Garcia Rubio, Spain**

Co-Director of the National Institute of Vision

## Industry Leadership and Partnerships

CooperVision's leadership in myopia management extends far beyond innovation and product development. Through influential partnerships, participation developing standards of care, and industry recognition and awards, the company continues to shape the present and future of pediatric eye care.

## Elevating the Standard of Care

- In 2021, the **World Council of Optometry (WCO)**, in partnership with CooperVision, passed a resolution publicly declaring support for **myopia management as the standard of care**<sup>16</sup>
- The resolution has been signed by **70,000+ individuals** across **217 organizations**
- In addition, CooperVision and the WCO partnered in 2024 to develop **The WCO CooperVision Myopia Management Navigator** (myopianavigator.info), a practical, online resource designed to help eye care professionals around the world implement this standard in everyday practice and improve outcomes for children everywhere

## Driving Progress Through Global Partnerships

CooperVision collaborates with leading organizations to expand access, awareness, and scientific progress in myopia management such as:

- Global Myopia Awareness Coalition (GMAC)
- International Agency for the Prevention of Blindness (IAPB)
- International Myopia Institute (IMI)
- Myopia Profile
- World Council of Optometry (WCO)
- World Society of Paediatric Ophthalmology and Strabismus (WSPOS)
- British Contact Lens Association (BCLA)

## Recognized for Innovation and Impact

- **2018** Optician Award, Contact Lens Product of the Year, U.K.
- **2019** BCLA Industry Award, U.K.
- **2020** Contact Lens Spectrum Product of the Year, U.S.
- **2020** Popular Science "Best of What's New" Award, U.S.
- **2021** Health Care Asia MedTech Award, Asia
- **2021** Garland W. Clay Award (AAO), U.S., for most-cited paper in Optometry and Vision Science
- **2022** German Innovation Awards, Special Mention in the Excellence in Business to Consumer, Medical, and Health category, Germany
- **2024** Fast Company Most Innovative Companies (award received for MiSight® 1 day), U.S.
- **2024** Wavefront Congress Luminary, Arthur Bradley (recognized for contributions to MiSight® 1 day), Europe
- **2025** Garland W. Clay Award (AAO), U.S., for most-cited paper in Optometry and Vision Science

*"As a parent, you absolutely want the best for your children. I think had my son Dan not been on this trial for myopia management I really don't know whether or not he would be in the Army today following his dream of his military career."*

**Donna Tennant**  
MiSight® 1 day Parent

*"Children are so adaptable. We worry about compliance, we worry about handling, and we don't need to. Children are great, parents learn quickly, and the problems that you might expect don't materialize. Jump on the train, start the journey, and start offering myopia management to your patients because you owe it to them. You owe it to those children who are now a -6 but could have been a -3. Every year that you delay is more myopia to manage later."*

**Andy Britton, UK**  
Specialist Optometrist and Director Specsavers Haverfordwest



**CooperVision is committed to providing eye care professionals and communities with the tools, knowledge, and confidence to embrace myopia management.**

*"In the next five years, I hope to see every eye care professional actively prescribing myopia management, and our entire profession united in addressing this global pandemic together."*

**Dr. Aamena Kazmi, United States,  
Therapeutic Optometrist, Diplomate, ABO**

*"If I was to go back in time, I'd like to say to myself that it's never too early to start the myopia control conversation. The parent(s) and child might not be on board straight away but just planting that seed in their head is so important. The earlier we start, the better results we get and the better the chances of managing their myopia and slowing it down."*

**Celine Zhang, Optomotrest, V Vis Sci/B Optom(Hons),  
SpecCerts MMP (Optom) UniMelb Eyecare Plus Kareela and Bankstown in Sydney**



- <sup>1</sup> Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
- <sup>2</sup> Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. OVS 2022 Mar 1;99(3):204-212.
- <sup>3</sup> Chamberlain P, et al. Eye growth and myopia progression following cessation of myopia control therapy with a dual-focus soft contact lens. Optom and Vis Sci. 2025 Mar 25; (1):10.1097/OPX.0000000000002244.
- <sup>4</sup> Woods J, et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391.
- <sup>5</sup> Sulley A, et al. Experience and subjective responses for children switched from single vision to dual focus myopia control daily disposable contact lenses. BCLA paper presentation 2021.
- <sup>6</sup> Jakobsen, Møller. Control of myopia using orthokeratology lenses in Scandinavian children aged 6 to 12 years. Eighteen-month data from the Danish Randomized Study: Clinical study Of Near-sightedness; Treatment with Orthokeratology Lenses (CONTROL study). AO 2022 Mar;100(2):175-182.
- <sup>7</sup> Lu, et al. Efficacy of Trial Fitting and Software Fitting for Orthokeratology Lens: One-Year Follow-Up Study. ECL 2018 Sep;44(5):339-343.
- <sup>8</sup> Rappon, et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS) BJO Published Online First: 01 September 2022.
- <sup>9</sup> Laughton D, et al. Safety and Efficacy of a Novel Spectacle Lens for Myopia Control Over Three Years. OVS 2022; 99: E-abstract 220063.
- <sup>10</sup> CVI data on file 20254. Prospective, 1-week, double masked, randomized, bilateral crossover study with MiSight 1 day and MyDay MiSight 1 day silicone hydrogel. N=323 subjects aged 8-18 years.
- <sup>11</sup> Goldschmidt E, Jacobsen N. Genetic and environmental effects on myopia development and progression. Eye (Lond). 2014 Feb;28(2):126-133.
- <sup>12</sup> Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017 Sep;95(6):551-566.
- <sup>13</sup> Huang HM, Chang DS, Wu PC. The Association between Near Work Activities and Myopia in Children-A Systematic Review and Meta-Analysis. PLoS One. 2015 Oct 20;10(10):e0140419.
- <sup>14</sup> Lanca C, Saw SM. The association between digital screen time and myopia: A systematic review. Ophthalmic Physiol Opt. 2020 Mar;40(2):216-229
- <sup>15</sup> Holden BA, Frické TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.
- <sup>16</sup> Resolution: The standard of care for Myopia Management by Optometrists. World Council of Optometry. (2021, May 17). <https://worldcouncilofoptometry.info/resolution-the-standard-of-care-for-myopia-management-by-optometrists/>
- <sup>17</sup> Kate L. Gifford, Kathryn Richdale, Pauline Kang, Thomas A. Aller, Carly S. Lam, Y. Maria Liu, Langis Michaud, Jeroen Mulder, Janis B. Orr, Kathryn A. Rose, Kathryn J. Saunders, Dirk Seidel, J. Willem L. Tideman, Padmaja Sankaridurg; IMI - Clinical Management Guidelines Report. Invest. Ophthalmol. Vis. Sci. 2019;60(3):M184-M203. doi:10.1167/iov.18-25977
- <sup>18</sup> Xu L et al. High myopia and glaucoma susceptibility, the Beijing Eye Study. Ophthalmology. 2007;114(2):216-20
- <sup>19</sup> Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. PRER 2013;31(6):622-60.
- <sup>20</sup> Younan C, et al. Myopia and incident cataract and cataract surgery: the blue mountains eye study. IVOS 2002;43(12):3625-3632
- <sup>21</sup> Chen SJ, et al. Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai eye study. IOVS 2012;53(8):4868-73.
- <sup>22</sup> Walline J, et al. Randomized trial of the effect of contact lens wear on self-perception in children. Optom Vis Sci. 2009 Mar;86(3):222-32.
- <sup>23</sup> E. L. Lamoureux et al. Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). IOVS 2008;49(13):4469.
- <sup>24</sup> Chua S.Y.L., Foster P.J. (2020) The Economic and Societal Impact of Myopia and High Myopia:53-63. In: Ang M., Wong T. (eds) Updates on Myopia. Springer, Singapore.
- <sup>25</sup> Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363.
- <sup>26</sup> CVI Data on file 2025. Approximate wearing hours as reported across MiSight® 1 day completed and ongoing clinical studies and independent Published or In-Press Studies and real-world estimates, Data as of as of September 2024.
- <sup>27</sup> CVI Data on file 2025, MiSight 1 day and similar lens types - patients under 20.
- <sup>28</sup> CVI data on file 2025. Internal MiSight® 1 day global wearer modeling estimates for the 12-month period of June 2024 to May 2025.
- <sup>29</sup> Anstice NS, Phillips JR. Effect of dual-focus soft contact lens wear on axial myopia progression in children. Ophthalmology. 2011 Jun;118(6):1152-61. doi: 10.1016/j.ophtha.2010.10.035. Epub 2011 Jan 26. PMID: 21276616 [https://www.aajournal.org/article/S0161-6420\(10\)1154-1/abstract](https://www.aajournal.org/article/S0161-6420(10)1154-1/abstract) Effect of Dual-Focus Soft Contact Lens Wear on Axial Myopia Progression in Children - Ophthalmology
- <sup>30</sup> CVI data on file, 2024. Plastic Bank data on file, 2024.
- <sup>31</sup> CVI data on file 2022.
- <sup>32</sup> American Academy of Ophthalmology Leads Global Initiative to address worldwide myopia epidemic. American Academy of Ophthalmology. (2020, November 11). <https://www.aao.org/newsroom/news-releases/detail/academy-leads-initiative-to-address-myopia>
- <sup>33</sup> Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis British Journal of Ophthalmology 2025;109:362-371.
- <sup>34</sup> James S. Wolffsohn, Monica Jong, Earl L. Smith, Serge R. Resnikoff, Jost B. Jonas, Nicola S. Logan, Ian Morgan, Padmaja Sankaridurg, Kyoko Ohno-Matsui; IMI 2021 Reports and Digest - Reflections on the Implications for Clinical Practice Invest. Ophthalmol. Vis. Sci. 2021;62(5):1. <https://doi.org/10.1167/iov.62.5.1>
- <sup>35</sup> Chamberlain, Arumugam, et al. Myopia progression cessation of Dual-Focus contact lens wear: MiSight 1 day 7-year findings. OVS 2025 In Press;98:E-abstract 210049.
- <sup>36</sup> CVI data on file 20254. Prospective, 1-week, double masked, randomized, bilateral crossover study with MiSight 1 day and MyDay MiSight 1 day silicone hydrogel. N=323 subjects aged 8-18 years.
- <sup>37</sup> Lam HY et al. Long-term impact of daily disposable hydrogel soft contact lens wear on corneal endothelium in children. IOVS 2024;65: ARVO E-Abstract 6607.
- <sup>38</sup> Reshaping care: New myopia management guidance released. AOA. (2021, January 12). <https://www.aao.org/news/clinical-eye-care/diseases-and-conditions/new-myopia-management-guidance-released>
- <sup>39</sup> American Academy of Ophthalmology Leads Global Initiative to address worldwide myopia epidemic. American Academy of Ophthalmology. (2020, November 11). <https://www.aao.org/newsroom/news-releases/detail/academy-leads-initiative-to-address-myopia>
- <sup>40</sup> CVI data on file, 2024.
- <sup>41</sup> Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. OVS 2021;98:E-abstract 215130.
- <sup>42</sup> CVI data on file, 2025.
- <sup>43</sup> Chamberlain P et al. Six-year cumulative treatment effect and treatment efficacy of a dual focus myopia control contact lens. OPO 2024; 44:199-205.



CooperVision®

CooperVision® and MiSight® are registered trademarks of The Cooper Companies, Inc. and its subsidiaries.  
© 2025 CooperVision SA15637 Rev. #2 11/2025

Product, indications for use, and regulatory approvals vary by country. Please consult your local CooperVision representative or regulatory authority for region-specific information.

MiSight® 1 day